한빛사
>
한빛사논문
한빛사논문
- 조회233
Nat. Biomed. Eng., 28 November 2024 | https://doi.org/10.1038/s41551-024-01298-0
Diagnosis of early-stage bladder cancer via unprocessed urine samples at the point of care
Changjoon Keum 1,7, Haejin Yeom 1,2,7, Tae Il Noh 3,7, Seung Yong Yi 1,2, Soyeong Jin 1,4, Chaekyu Kim 5, Ji Sung Shim 3, Sung Goo Yoon 3, Hojun Kim 1, Kwan Hyi Lee 1,6,*, Seok Ho Kang 3,* & Youngdo Jeong 1,2,*
1Center for Advanced Biomolecular Recognition, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
2Department of HY-KIST Bio-convergence, Hanyang University, Seoul, Republic of Korea.
3Department of Urology, Korea University School of Medicine, Seoul, Republic of Korea.
4Department of Chemistry, Hanyang University, Seoul, Republic of Korea.
5Fusion Biotechnology, Inc., Ulsan, Republic of Korea.
6KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, Republic of Korea.
7These authors contributed equally: Changjoon Keum, Haejin Yeom, Tae Il Noh.
2Department of HY-KIST Bio-convergence, Hanyang University, Seoul, Republic of Korea.
3Department of Urology, Korea University School of Medicine, Seoul, Republic of Korea.
4Department of Chemistry, Hanyang University, Seoul, Republic of Korea.
5Fusion Biotechnology, Inc., Ulsan, Republic of Korea.
6KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, Republic of Korea.
7These authors contributed equally: Changjoon Keum, Haejin Yeom, Tae Il Noh.
*Corresponding authors: correspondence to Kwan Hyi Lee, Seok Ho Kang or Youngdo Jeong
Abstract
Diagnostic kits for the optical detection of bladder cancer in urine can facilitate effective screening and surveillance. However, the heterogeneity of urine samples, owing to patients with bladder cancer often presenting with haematuria, interfere with the transduction of the optical signal. Here we describe the development and point-of-care performance of a device for the detection of bladder cancer that obviates the need for sample processing. The device leverages the enzymatic release of organogel particles carrying solvatochromic fluorophores in the presence of urinary hyaluronidases—a bladder cancer biomarker. Owing to buoyancy, the particles transfer from the urine sample into the organic phase, where the change in fluorescence can be measured via a smartphone without interference from blood proteins. In a double-blind study with 80 unprocessed urine samples from patients with bladder cancer (including samples with haematuria) or other genitourinary diseases and with 25 samples from healthy participants, our system distinguished the cancerous samples, including those with early-stage bladder cancer, with accuracies of about 90%. Obviating the need for sample pretreatment may facilitate the at-home detection of bladder cancer.
논문정보
- Research article
- 2024년 11월 (BRIC 등록일 2024-11-29)
- 국내 연구진
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
관련분야 논문보기
